ERXC 101
Alternative Names: ERXC-101Latest Information Update: 25 Oct 2022
At a glance
- Originator EnduRx Pharmaceuticals; M. D. Anderson Cancer Center
- Class Antineoplastics; Polymers
- Mechanism of Action Mitochondrial protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Breast cancer; Solid tumours
Most Recent Events
- 13 Oct 2022 Preclinical trials in Breast cancer in USA (unspecified route) prior to October 2022 (EnduRx Pharmaceuticals pipeline, October 2022)
- 13 Oct 2022 Preclinical trials in Solid tumours in USA (unspecified route) prior to October 2022 (EnduRx Pharmaceuticals pipeline, October 2022)
- 13 Oct 2022 EnduRx Pharmaceuticals announces intention to submit IND for ERXC 101 in 2023 (EnduRx Pharmaceuticals pipeline, October 2022)